Genetically Engineered Macrophages Derived from iPSCs for Self-Regulating Delivery of Anti-Inflammatory Biologic Drugs
Journal of Tissue Engineering and Regenerative Medicine · 06.01.2024 · 2024 · 1-11
DOI: 10.1155/2024/6201728 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Tissue Engineering and Regenerative Medicine, erschienen am 06.01.2024. Verfasst von Molly Klimak und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Washington University, St. Louis, MO 63110, USA. Hauptthemen laut MEDLINE: Induced Pluripotent Stem Cells, Biological Products. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, NIA NIH HHS, Shriners Hospitals for Children.
Abstract (Originalsprache)
In rheumatoid arthritis, dysregulated cytokine signaling has been implicated as a primary factor in chronic inflammation. Many antirheumatic and biological therapies are used to suppress joint inflammation, but despite these advances, effectiveness is not universal, and delivery is often at high doses, which can predispose patients to significant off-target effects. During chronic inflammation, the inappropriate regulation of signaling factors by macrophages accelerates the progression of disease by driving an imbalance of inflammatory cytokines, making macrophages an ideal cellular target. To develop a macrophage-based therapy to treat chronic inflammation, we engineered a novel induced pluripotent stem cell (iPSC)-derived macrophage capable of delivering soluble TNF receptor 1 (sTNFR1), an anti-inflammatory biologic inhibitor of tumor necrosis factor alpha (TNF-α), in an autoregulated manner in response to TNF-α. Murine iPSCs were differentiated into macrophages (iMACs) over a 17-day optimized protocol with continued successful differentiation confirmed at key timepoints. Varying inflammatory and immunomodulatory stimuli demonstrated traditional macrophage function and phenotypes. In response to TNF-α, therapeutic iMACs produced high levels of sTNFR1 in an autoregulated manner, which inhibited inflammatory signaling. This self-regulating iMAC system demonstrated the potential for macrophage-based drug delivery as a novel therapeutic approach for a variety of chronic inflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, Washington University, St. Louis, MO 63110, USA.
- Shriners Hospitals for Children - St. Louis, St. Louis, MO 63110, USA.
- Department of Biomedical Engineering, Washington University, St. Louis, MO 63110, USA.
- Center of Regenerative Medicine, Washington University, St. Louis, MO 63110, USA.
Förderung
- NIAMS NIH HHS
- NIA NIH HHS
- Shriners Hospitals for Children
- National Institutes of Health
Zitieren
APA
Klimak, M., & Guilak, F. (2024). Genetically Engineered Macrophages Derived from iPSCs for Self-Regulating Delivery of Anti-Inflammatory Biologic Drugs. Journal of Tissue Engineering and Regenerative Medicine, 2024, 1-11. https://doi.org/10.1155/2024/6201728
Vancouver
Klimak M, Guilak F. Genetically Engineered Macrophages Derived from iPSCs for Self-Regulating Delivery of Anti-Inflammatory Biologic Drugs. Journal of Tissue Engineering and Regenerative Medicine. 2024;2024:1-11. doi:10.1155/2024/6201728
BibTeX
@article{Klimak2024,
author = {Klimak, Molly and Guilak, Farshid},
title = {Genetically Engineered Macrophages Derived from iPSCs for Self-Regulating Delivery of Anti-Inflammatory Biologic Drugs},
journal = {Journal of Tissue Engineering and Regenerative Medicine},
year = {2024},
volume = {2024},
pages = {1--11},
doi = {10.1155/2024/6201728}
}
EUVIMED